Terms ending in 2041
Every in-force patent on Codexis, Inc.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,331,325 | Engineered Transaminase Polypeptides In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 11,987,823 | Engineered Lipase Variants In force · High confidence | Societe des Produits Nestle S.A. | In force | High confidence | |
| US 11,788,071 | Engineered Transaminase Polypeptides In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,241,100 | Engineered Leucine Decarboxylases In force · High confidence | Syntis Bio, Inc. | In force | High confidence | |
| US 11,767,519 | Engineered Amylase Variants In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,071,642 | Engineered Amylase Variants In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,275,962 | Engineered Acetate Kinase Variant Enzymes In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,215,359 | Engineered Glucose Dehydrogenases and Methods for the Reductive Amination of Ketone and Amine Compounds In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 11,959,108 | Engineered Protease Variants In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,344,865 | Biocatalysts and Methods for Hydroxylation of Chemical Compounds In force · High confidence | Codexis, Inc. | In force | High confidence | |
| 1 more term end in 2041 · Pro | |||||
10 of 11 patents shown. Soonest term end first, then patent number.
Pro members see all 11.
9 of these are in force and held by Codexis, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.